


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 080421-000100US
Client Ref. No.: 80021-255



On October 12, 2006

By TOWNSEND and TOWNSEND and CREW LLP

By: Jo Ann Honcik Dallara
Jo Ann Honcik Dallara

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

TUDAN *et al.*

Application No.: 10/086,177

Filed: February 26, 2002

For: CXC CHEMOKINE RECEPTOR 4
AGONIST PEPTIDES

Customer No. 20350

Confirmation No. 1250

Examiner: Bunner, Bridget E.

Art Unit: 1647

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Amendment accompanies a Request for Continued Examination and is responsive to the Final Office Action mailed October 12, 2005, on the above-referenced application. A Notice of Appeal was filed on March 13, 2006. On July 24th, a three month extension for response was paid and an additional two month petition for extension accompanies the RCE. If any additional fee is required, the Commissioner is authorized to deduct such a fee from the undersigned's Deposit Account No. 20-1430.

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825,

Appl. No. 10/086,177
Amdt. dated Oct. 12, 2006
Reply to Final Office Action of Oct. 12, 2005

PATENT

Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing.

Please enter and consider the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 40 of this paper.

Remarks/Arguments begin on page 41 of this paper.